Chronic mucocutaneous candidiasis (CMCC) is a rare disorder in which abnormalities of immune function are frequently demonstrable (Kirkpatrick et al. 1971) . As a result of the work of Higgs & Wells (1972) four main clinical groups are recognized: (I) familial; (2) in association with endocrinopathy; (3) late onset in association with malignancy, particularly thymoma; and (4) the diffuse variety. The patient now described is thought to suffer from diffuse chronic mucocutaneous candidiasis. An interesting association between poor intestinal absorption of iron and CMCC has also been recorded, with patients demonstrating clearance of lesions when a low level of serum iron is raised by parental iron therapy (Higgs 1973) .
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Case report
A 25-year-old Caucasian female presented with a 20-year history of oral lesions, and a 13-year history of paronychia and vaginitis. Candida albieans had been grown on many occasions from all affected sites, but clinical improvement had not followed intensive therapy with topical nystatin and amphotericin B. There was no family history of candidiasis or other evidence of immunodeficiency, but the patient herself had a history of recurrent respiratory infections and two attacks of herpes zoster in childhood.
Investigations: Significant abnormalities in specific candida-related immune function were: raised serum levels of anticandida IgG and absent anticandida IgA (measured by the method of Nielsen et al. 1973 ), absent lymphocyte transformation or leukocyte migration inhibitory factor on exposure to candida antigen, and a negative candida skin test (read at 48 hours). General tests of immune function showed a relatively low level of lymphocyte transformation on exposure to phytohaemagglutinin (PHA) and a relatively high level of transformation on exposure to pokeweed mitogen (PWM). Total immunoglobulin levels were within the normal range and a nitroblue tetrazolium test showed no abnormality of neutrophil function. Skin testing with purified protein derivative (PPD) was negative despite a history of BCG vaccination. No haematological or biochemical abnormalities were detected and although the patient's serum iron was initially low it rose to normal levels after oral iron therapy with no change in the clinical state.
Therapy: Transfer factor (I unit) was prepared by the method of Lawrence (1974) from one pint of blood from a donor demonstrating strongly positive 48-hour skin tests to both PPD and candida. This was administered subcutaneously and the dose repeated at 6 to 7 week intervals. Intensive topical antifungal therapy was also maintained.
Results: Clinically there has been considerable improvement in oral and vaginal lesions. The nails infected with candida have been removed with no recurrence of infection. If there is a delay of longer than 8-10 weeks between the administration of units of transfer factor, both oral and vaginal lesions recur. An oesophageal stricture from which candida has been cultured is now present but responds to periodical dilatation.
The most striking candida-specific immunological change during transfer factor therapy has been the initial sharp rise in levels of anticandida antibodies. Anticandida IgG rose within I Papers read to Section of Dermatology, 15 December 1977. Accepted 2 October 1978 a week of the first administration of transfer factor to an extremely high level of 870 units/rnl (normal level up to 150 units/ml) and then rapidly fell to a level only slightly above normal. Anticandida IgM rose from 50 to 250 units (normal level up to 100 units/ml) and then fell to 40 units, and anticandida IgA was detected in the serum for the first time. Levels of all three anticandida antibodies are currently in the high normal range, lymphocyte transformation to candida antigen is present and leukocyte migration inhibitory factor is produced on exposure of leukocytes to candida antigen.
Changes in nonspecific immune function have been from a PPD negative skin test to positivity after the second unit of transfer factor, and a rise in the responsiveness of peripheral blood lymphocytes to PHA stimulation. No changes in total levels of IgG, IgA or IgM have been detected during the periods of fluctuation of specific anticandida antibodies.
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The term transfer factor is given to dialysable material present in extracts of immune peripheral blood leukocytes which apparently confers ('transfers') delayed-type hypersensitivity (or its in vitro correlates) when injected into a non-hypersensitive subject. Clinical and immunological' observations following the administration of transfer factor have led to the concept that it converts non-immune to immune lymphocytes in vivo, thus acting as a mediator of adoptive sensitization (Lawrence 1974) . A wide variety of clinical conditions including immunodeficiency, infectious diseases, autoimmunity and malignancy have therefore been treated with transfer factor in attempts to reconstitute cellular immunity. However, the mechanism by which transfer factor is therapeutically beneficial is. complicated by clinical observations that patients may acquire cellular immune responsiveness not apparently related to donor specificity (Dupont et al. 1974 , Valdimarsson et al. 1974 , Spitler et al. 1972 , Griscelli 1975 , Kirkpatrick & Smith 1976a suggesting that leukocyte extracts may also possess adjuvant properties. The clinical benefit derived from treatment with transfer factor may therefore depend not only on the initiation of specific immunological reactivity, but also the amplification 'of an existing immune response.
The proposition that both the so-called specific and nonspecific properties of transfer factor may have a contribution to make to the augmentation of cellular immune responses in patients raises a number of practical issues. It is perhaps useful to remember that the term transfer factor is often applied to the whole leukocyte extract administered in vivo. However, it has been suggested that the crude material be termed 'dialysable leukocyte extract' and that the term 'transfer factor' be reserved for the unidentified factor or factors capable of transferring delayed hypersensitivity. The relative roles of the specific and nonspecific activities in the extract raise questions regarding the selection of donors for therapy. It is not clear whether a more beneficial product may be prepared from donors with specific strong delayed hypersensitivity responses or from unscreened pooled normal healthy donors. The question is oI41-0768/79/120927--{)3/$0 I,00/0
